Cargando…

PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis

Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, HAN, ZHOU, YINGYING, ZHANG, SIYANG, QI, YA, WANG, MIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208018/
https://www.ncbi.nlm.nih.gov/pubmed/37303939
http://dx.doi.org/10.32604/or.2022.03561
_version_ 1785046580755169280
author WANG, HAN
ZHOU, YINGYING
ZHANG, SIYANG
QI, YA
WANG, MIN
author_facet WANG, HAN
ZHOU, YINGYING
ZHANG, SIYANG
QI, YA
WANG, MIN
author_sort WANG, HAN
collection PubMed
description Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the transcripts of small nucleolar RNA host gene SNHG16-L/S were differentially expressed in OC cells and tissues as detected through real-time PCR (RT-PCR). SNHG16-L/S had opposite effects on progression and PTX resistance in OC. Mechanistically, SNHG16-L inhibited GATA-binding protein 3 (GATA3) transcription by binding to CCAAT/enhancer-binding protein B (CEBPB). Moreover, PRPF6 induced the alternative splicing of SNHG16, causing downregulation of SNHG16-L and, leading to the upregulation of GATA3 expression to further promote metastasis and PTX-resistance in OC. Totally, these data unveiled that PRPF6 promotes metastasis and PTX resistance of OC through SNHG16-L/CEBPB/GATA3 axis, which provides a new direction for OC treatment.
format Online
Article
Text
id pubmed-10208018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-102080182023-06-10 PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis WANG, HAN ZHOU, YINGYING ZHANG, SIYANG QI, YA WANG, MIN Oncol Res Article Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the transcripts of small nucleolar RNA host gene SNHG16-L/S were differentially expressed in OC cells and tissues as detected through real-time PCR (RT-PCR). SNHG16-L/S had opposite effects on progression and PTX resistance in OC. Mechanistically, SNHG16-L inhibited GATA-binding protein 3 (GATA3) transcription by binding to CCAAT/enhancer-binding protein B (CEBPB). Moreover, PRPF6 induced the alternative splicing of SNHG16, causing downregulation of SNHG16-L and, leading to the upregulation of GATA3 expression to further promote metastasis and PTX-resistance in OC. Totally, these data unveiled that PRPF6 promotes metastasis and PTX resistance of OC through SNHG16-L/CEBPB/GATA3 axis, which provides a new direction for OC treatment. Tech Science Press 2022-08-31 /pmc/articles/PMC10208018/ /pubmed/37303939 http://dx.doi.org/10.32604/or.2022.03561 Text en © 2022 Wang et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
WANG, HAN
ZHOU, YINGYING
ZHANG, SIYANG
QI, YA
WANG, MIN
PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title_full PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title_fullStr PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title_full_unstemmed PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title_short PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis
title_sort prpf6 promotes metastasis and paclitaxel resistance of ovarian cancer via snhg16/cebpb/gata3 axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208018/
https://www.ncbi.nlm.nih.gov/pubmed/37303939
http://dx.doi.org/10.32604/or.2022.03561
work_keys_str_mv AT wanghan prpf6promotesmetastasisandpaclitaxelresistanceofovariancancerviasnhg16cebpbgata3axis
AT zhouyingying prpf6promotesmetastasisandpaclitaxelresistanceofovariancancerviasnhg16cebpbgata3axis
AT zhangsiyang prpf6promotesmetastasisandpaclitaxelresistanceofovariancancerviasnhg16cebpbgata3axis
AT qiya prpf6promotesmetastasisandpaclitaxelresistanceofovariancancerviasnhg16cebpbgata3axis
AT wangmin prpf6promotesmetastasisandpaclitaxelresistanceofovariancancerviasnhg16cebpbgata3axis